GCTK
GlucoTrack, Inc. NASDAQ$0.80
Mkt Cap $719,528
52w Low $0.62
1.2% of range
52w High $15.90
50d MA $1.08
200d MA $4.28
P/E (TTM)
-0.0x
EV/EBITDA
0.2x
P/B
0.2x
Debt/Equity
0.0x
ROE
-685.6%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$1.08
200d MA
$4.28
Avg Volume
1.2M
About
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | — | -3.98 | — | 0.76 | -7.6% | -14.1% | +5.7% | +13.6% | +9.7% | -9.8% | +21.7% | — |
| Nov 13, 2025 | AMC | — | -4.64 | — | 5.67 | -10.1% | -8.6% | -8.3% | -13.2% | -10.6% | -12.5% | -9.2% | — |
| Aug 14, 2025 | AMC | — | -9.62 | — | 5.72 | +0.2% | +0.9% | +0.0% | -6.1% | -5.1% | -4.7% | +36.0% | — |
| May 14, 2025 | AMC | — | -20.36 | — | 8.98 | -1.8% | +0.1% | +0.3% | -3.1% | -0.3% | -6.5% | -36.6% | — |
| Mar 27, 2025 | AMC | — | 10.00 | — | 13.94 | -9.2% | -11.8% | -24.9% | -3.2% | -13.8% | -19.5% | -25.1% | — |
| Nov 14, 2024 | AMC | — | -1089.82 | — | 370.20 | -2.4% | -12.2% | -6.6% | -17.3% | -13.8% | -19.0% | -16.7% | — |
| Aug 13, 2024 | AMC | — | -982.04 | — | 1762.80 | +2.1% | +10.9% | +36.1% | +40.2% | +60.0% | +60.7% | +100.1% | — |
| May 15, 2024 | AMC | — | -718.56 | — | 2964.00 | -2.6% | -0.8% | +1.2% | -4.3% | -4.9% | -12.6% | -2.8% | — |
| Mar 28, 2024 | AMC | — | -598.80 | — | 1986.60 | -2.6% | -1.2% | +6.2% | +20.3% | +20.6% | +50.7% | +69.1% | — |
| Nov 14, 2023 | AMC | — | -0.10 | — | 954.60 | +0.6% | +5.2% | +0.6% | -3.5% | +13.2% | +8.2% | +56.9% | — |
Recent Filings
8-K · 1.01
!! High
GlucoTrack, Inc. -- 8-K 1.01: Material Agreement
GlucoTrack, Inc. entered into an exchange agreement that could affect shareholder equity structure, though full details on the counterparty and consideration remain unclear from this brief disclosure.
Apr 30
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
A major shareholder's convertible note includes a 19.9% ownership cap, limiting dilution but potentially creating uncertainty about future capital raise flexibility for GCTK.
Apr 14
8-K
Unknown — 8-K Filing
Glucotrack advanced its core implantable glucose monitoring technology in 2025, positioning the company for potential future commercialization that could address a large diabetes management market if clinical success continues.
Mar 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Glucotrack's planned US clinical trial launch and FDA IDE submission in 2026 signal regulatory progress for its diabetes monitoring technology, potentially validating its development strategy and creating a near-term catalyst for investor optimism.
Mar 27
8-K
Unknown — 8-K Filing
GCTK issued over 20% of outstanding shares in a private placement, diluting existing shareholders significantly and requiring Nasdaq approval under Rule 5635.
Mar 13
Data updated apr 25, 2026 10:53am
· Source: massive.com